Korea's CJ CheilJedang and Japan's RaQualia Pharma Partner For Gastrointestinal Therapies
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's CJ CheilJedang signed a memorandum of understanding and subsequently a licensing agreement with Japan's RaQualia Pharma to establish a strategic alliance for the latter's innovative gastrointestinal therapies
You may also be interested in...
Pfizer Japan Spinout RaQualia Cuts Another Deal With Korea's CJ CheilJedang
SEOUL - In a follow-up to a memorandum of understanding signed in 2010, CJ CheilJedang Corp. signed an agreement with RaQualia Pharm Inc. for exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 partial agonist (RQ-0010) in South Korea, China, Taiwan, India and Southeast Asia
Pfizer Japan Spinout RaQualia Cuts Another Deal With Korea's CJ CheilJedang
SEOUL - In a follow-up to a memorandum of understanding signed in 2010, CJ CheilJedang Corp. signed an agreement with RaQualia Pharm Inc. for exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 partial agonist (RQ-0010) in South Korea, China, Taiwan, India and Southeast Asia
Samsung Group Set To Enter Biosimilars Market With $1.9 Billion Investment
SEOUL - Samsung Group has ended years of exploration for new business realms beyond its traditional pipeline of semiconductors and electronics products; South Korea's leading conglomerate is set to enter the healthcare sector, particularly biosimilars and medical devices, with an initial investment of roughly $4.1 billion